行情

INO

INO

Inovio制药
NASDAQ

实时行情|Nasdaq Last Sale

3.810
-0.410
-9.72%
盘前: 3.870 +0.06 +1.57% 07:17 02/20 EST
开盘
4.210
昨收
4.220
最高
4.290
最低
3.610
成交量
1,438.54万
成交额
--
52周最高
5.95
52周最低
1.915
市值
3.77亿
市盈率(TTM)
-3.2412
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INO 新闻

  • Here's Why Inovio Pharmaceuticals Popped Today
  • MotleyFool.com.1天前
  • Sanofi Gets Backing From U.S. Government to Develop a COVID-19 Vaccine
  • MotleyFool.com.1天前
  • The Wuhan Virus and Research-Focused Biotech Companies
  • GuruFocus.com.1天前
  • Inovio Pharmaceuticals Option Alert: Fri $4 Calls Sweep (23) near the Ask: 656 @ $0.5 vs 10774 OI; Earnings 3/10 After Close [est] Ref=$4.215
  • Benzinga.1天前

更多

所属板块

生物技术和医学研究
+1.01%
制药与医学研究
+0.22%

热门股票

名称
价格
涨跌幅

INO 简况

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
展开

Webull提供Inovio Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。